![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim
We assessed an autoantibody against new gene expressed in prostate (NGEP) protein for prostate cancer (PCa) that may better diagnosis and prognosis approaches in the patients with PCa.
Methods
Autoantibodies against NGEP were measured in sera of PCa patients by ELISA.
Results
The autoantibody against NGEP is present in a significantly higher proportion in the sera of PCa patients as compared with healthy controls (p < 0.001). An inverse significant correlation was found between seropositive patients and Gleason score (p < 0.05) and serum prostate-specific antigen (recombinant NGEP; p < 0.05).
Conclusion
The data showed that measurement of autoantibody against NGEP as a novel prostate-specific antigen in sera can be used as a potential biomarker to discriminate well-differentiated PCa patients from normal subjects.
Financial & competing interest disclosure
This study was conducted as a research project and supported by a grant from Iran University of Medical Sciences (grant number: #117-28789) and Iranian National Science Foundation (grant number: #89002533). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical approval
This study was approved by Iran University of Medical Sciences. All procedures performed in this study were in accordance with the the ethical standards of the Institution at which the study was conducted and the 1964 Helsinki Declaration and its later amendments.